GO
Loading...

Johnson & Johnson

More

  • Midday Glance: Pharmaceuticals companies Friday, 6 Mar 2015 | 1:25 PM ET

    Baxter International Inc. fell $1.02 or 1.5 percent, to $68.19. Bristol-Myers Squibb Co. fell$. 71 or 1.1 percent, to $65.34. Eli Lilly& Co. fell $1.31 or 1.9 percent, to $69.28.

  • Midday Glance: Medical Devices companies Friday, 6 Mar 2015 | 1:25 PM ET

    Allergan fell $1.26 or. 5 percent, to $234.15. Baxter International Inc. fell $1.02 or 1.5 percent, to $68.19. Boston Scientific Corp. fell$. 36 or 2.1 percent, to $16.61.

  • Early Glance: Pharmaceuticals companies Friday, 6 Mar 2015 | 10:57 AM ET

    Baxter International Inc. fell$. 83 or 1.2 percent, to $68.38. Bristol-Myers Squibb Co. fell$. 35 or. 5 percent, to $65.70. Eli Lilly& Co. fell $1.21 or 1.7 percent, to $69.38.

  • Early Glance: Medical Devices companies Friday, 6 Mar 2015 | 10:57 AM ET

    Allergan fell$. 61 or. 3 percent, to $234.80. Baxter International Inc. fell$. 83 or 1.2 percent, to $68.38. Boston Scientific Corp. fell$. 26 or 1.5 percent, to $16.71.

  • *FDA set to decide on approval of Novartis' Zarxio. LONDON/ LOS ANGELES, March 6- A revolution is brewing in healthcare with lower-cost copies of complex biotech drugs finally set to reach the United States, nine years after so-called biosimilars were launched in Europe. The first approval for a biosimilar in the United States is expected imminently- Zarxio,...

  • Final Glance: Medical Devices companies Thursday, 5 Mar 2015 | 6:03 PM ET

    Allergan fell$. 27 or. 1 percent, to $235.41. Baxter International Inc. fell$. 04 or. 1 percent, to $69.21. Boston Scientific Corp. rose$. 18 or 1.1 percent, to $16.97.

  • Final Glance: Pharmaceuticals companies Thursday, 5 Mar 2015 | 6:03 PM ET

    Baxter International Inc. fell$. 04 or. 1 percent, to $69.21. Bristol-Myers Squibb Co. rose$. 38 or. 6 percent, to $66.05. Eli Lilly& Co. fell$. 06 or. 1 percent, to $70.59.

  • March 5- A California jury on Thursday ordered Johnson& Johnson's Ethicon Inc unit to pay $5.7 million in the first trial over injuries blamed on the TVT Abbrevo, one of numerous transvaginal mesh products that are the subject of thousands of lawsuits. Following more than three days of deliberations in Kern County, California, jurors found Ethicon liable for...

  • Midday Glance: Medical Devices companies Thursday, 5 Mar 2015 | 1:29 PM ET

    Allergan fell$. 89 or. 4 percent, to $234.79. Baxter International Inc. fell$. 29 or. 4 percent, to $68.96. Boston Scientific Corp. rose$. 10 or. 6 percent, to $16.89.

  • Midday Glance: Pharmaceuticals companies Thursday, 5 Mar 2015 | 1:29 PM ET

    Baxter International Inc. fell$. 29 or. 4 percent, to $68.96. Eli Lilly& Co. fell$. 08 or. 1 percent, to $70.57. Hospira fell$. 08 or. 1 percent, to $87.87.

  • Early Glance: Pharmaceuticals companies Thursday, 5 Mar 2015 | 11:23 AM ET

    Baxter International Inc. rose$. 20 or. 3 percent, to $69.45. Bristol-Myers Squibb Co. rose $1.42 or 2.2 percent, to $67.09. Eli Lilly& Co. rose$. 27 or. 4 percent, to $70.92.

  • Early Glance: Medical Devices companies Thursday, 5 Mar 2015 | 11:23 AM ET

    Allergan fell$. 09 or percent, to $235.59. Baxter International Inc. rose$. 20 or. 3 percent, to $69.45. Boston Scientific Corp. rose$. 10 or. 6 percent, to $16.89.

  • March 5- AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday. Deutsche Bank analyst...

  • *AbbVie to pay $261.25 per share in cash and stock. The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago- based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical...

  • AbbVie will spend about $21 billion to buy fellow drugmaker Pharmacyclics and add another major revenue producer to a portfolio that already includes the world's top-selling drug. AbbVie executives told analysts on Thursday that their company could reap more than $7 million in annual sales from Imbruvica in a few years. While AbbVie touted the potential...

  • March 4- Johnson& Johnson is close to buying cancer drug maker Pharmacyclics Inc in the coming days, the Financial Times reported, citing sources. A bid from J&J is expected to value Pharmacyclics near its $17.5 billion market value or at a premium, FT said on Wednesday, citing people familiar with the matter. Bloomberg reported last month, citing sources, that...

  • Report: J&J close to deal to buy partner Pharmacyclics Wednesday, 4 Mar 2015 | 6:24 PM ET

    Health care giant Johnson& Johnson reportedly is close to buying biopharmaceutical company Pharmacyclics, its longtime partner in developing blood cancer treatment Imbruvica. London's Financial Times reports "people familiar with the matter" say Johnson& Johnson's anticipated offer would value Pharmacyclics of Sunnyvale, California, above its current...

  • Final Glance: Pharmaceuticals companies Wednesday, 4 Mar 2015 | 6:17 PM ET

    Baxter International Inc. fell$. 17 or. 2 percent, to $69.25. Bristol-Myers Squibb Co. rose $3.75 or 6.1 percent, to $65.67. Eli Lilly& Co. rose$. 28 or. 4 percent, to $70.65.

  • Final Glance: Medical Devices companies Wednesday, 4 Mar 2015 | 6:17 PM ET

    Allergan rose$. 82 or. 3 percent, to $235.68. Baxter International Inc. fell$. 17 or. 2 percent, to $69.25. Boston Scientific Corp. rose$. 03 or. 2 percent, to $16.79.

  • After-hours buzz: Vivint, H&R Block, Encana & more Wednesday, 4 Mar 2015 | 5:20 PM ET

    Check out which companies are making headlines after the bell Wednesday: Vivint Solar, H&R Block, Encana & more.